Trials of tuberculosis-prevention interventions in Africa: A descriptive cross-sectional study

ID: 

1104

Session: 

Poster session 1 Wednesday: Evidence production and synthesis

Date: 

Wednesday 13 September 2017 - 12:30 to 14:00

Location: 

Exhibition Halls 1 & 2

All authors in correct order:

Titi N1, Pienaar E2, Musengimana G3, Abrams A2, Lutje V4, Kredo T2
1 Grants, Innovation and Product Development Unit, South African Medical Research Council, South Africa
2 Cochrane South Africa, South African Medical Research Council, South Africa
3 Division of Community Health, University of Stellenbosch, South Africa
4 International Health Research Group, Liverpool School of Tropical Medicine, UK
Presenting author and contact person

Presenting author:

Nondwe Titi

Contact person:

Nondwe Titi
Abstract text
Background: Prevention of new infections of Mycobacterium tuberculosis (TB) and their progression to disease is important for reducing the TB disease burden and related mortality. Randomised controlled trials (RCTs) are considered the gold standard for evaluating the effectiveness of healthcare interventions.

Objectives: Our study aimed to identify and describe published RCTs conducted in Africa for TB prevention, and assess their methodological quality. This work maps available published TB-prevention trials and identifies gaps to inform relevant key stakeholders in the TB field.

Methods: We searched 3 electronic databases: PubMed, EMBASE, and Cochrane Library in April 2015. All published RCTs investigating TB prevention in Africa were included. Two investigators independently screened records for inclusion and extracted data using a pre-defined data-extraction form. Data extracted included country, setting, interventions, funders, principal investigator, ethics and methodological quality which was assessed using Cochrane’s Risk-of-Bias tool. Descriptive analysis was conducted in MS Excel.

Results: A total of 7077 records were identified and 46 trials met the eligibility criteria, Figure 1. Trials were published between 1952 and 2015, and included a median sample size of 210 participants (range 18 to 121 020). Twenty-eight trials investigated vaccines, 15 investigated TB-preventive chemotherapy, two evaluated active case-finding, and one was a combination of BCG and TB-preventive chemotherapy interventions. Most trials were conducted in South Africa (n = 28), Figure 2. International agencies and governments were the predominant funders. Methodological quality of trials was poorly reported.

Conclusions: Studies mapping research in particular sectors can guide research and funding gaps, and highlight methodological strengths and limitations of the research conducted. In addition to the focus on vaccines and TB-preventive chemotherapy in African TB-prevention trials, researchers, governments and funders should consider increasing research on multi-faceted strategies to address transmission and active linkage to prevention services.

Attachments: 

PDF icon Fig 1.pdf
PDF icon Fig 2.pdf